Bioactivx Pte Ltd

Bioactivx Pte Ltd, headquartered in Singapore, focuses on developing innovative synthetic materials for wound care and tissue repair, significantly enhancing healing processes for various types of wounds. Founded in 2023, Bioactivx Pte Ltd specializes in synthetic regenerative materials aimed at wound care. In November 2025, Bioactivx Pte Ltd raised USD 1. 43 million in seed funding led by Cocoon Capital.

Bioactivx® specializes in synthetic, regenerative materials designed for wound care and tissue repair, with a core focus on their flagship product, the Bioactiv® Matrix. This next-generation skin substitute is engineered to expedite the healing of both acute and chronic wounds, such as burns, ulcers, cuts, and abrasions, by promoting skin regeneration and managing inflammation. The biomaterial platform utilizes animal-free, bioinspired technology that mimics natural healing processes, thus addressing the critical need for improved wound recovery solutions. Bioactivx® targets healthcare providers, particularly plastic, reconstructive, and vascular surgeons, who aim to enhance patient outcomes with advanced wound-care solutions.

The company is currently preparing for regulatory submission, indicating a strategic focus on markets in North America, Europe, and Asia, where demand for innovative wound care products is growing. The company's revenue structure revolves around direct partnerships with healthcare facilities and practitioners who incorporate the Bioactiv® Matrix into their treatment protocols. Transactions occur on a B2B basis, wherein hospitals and clinics procure the Bioactiv® Matrix and other future products for patient care. While specific pricing details for their flagship product are not disclosed, the firm is positioned to offer customizable wound care solutions that appeal to various healthcare providers.

As the company advances its product line and scales its operations, the focus remains on transforming the wound care landscape through innovative, regenerative medical implants that meet the evolving needs of patients and healthcare professionals alike. The company plans to use the funding from November 2025 to accelerate its clinical and regulatory approval of Bioactiv® Matrix, develop new products including Bioactiv® Foam and Bioactiv® Cellulose, and expand its production facility in Singapore.